TELA Bio, Inc. (TELA)
| Market Cap | 220.36M |
| Revenue (ttm) | 20.36M |
| Net Income (ttm) | -29.71M |
| Shares Out | 14.44M |
| EPS (ttm) | -2.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $15.26 |
| Previous Close | $15.50 |
| Change ($) | -0.24 |
| Change (%) | -1.55% |
| Day's Open | 15.55 |
| Day's Range | 15.26 - 15.53 |
| Day's Volume | 4,071 |
| 52-Week Range | 11.03 - 18.00 |
Mr. Paul Wilson, Consultant General Surgeon, successfully completes complex hernia repair with minimally invasive approach Mr. Paul Wilson, Consultant General Surgeon, successfully completes complex her...
OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021
MALVERN, Pa., June 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...
MALVERN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mate...
TELA Bio Inc (NASDAQ: TELA) has launched its second post-market study, BRAVO II, to evaluate the clinical performance of OviTex Reinforced Tissue Matrices in the robotic repair of ventral hernias. The s...
MALVERN, Pa., May 19, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mate...
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -27.27% and 4.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of TELA Bio (NASDAQ:TELA) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 11.11% year over year to ($0.56), which missed the estim...
MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue rei...
TELA Bio, Inc. (TELA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement ma...
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -5.88% and 1.20%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of TELA Bio (NASDAQ:TELA) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share increased 55.74% over the past year to ($0.54), which missed the estimate of (...
MALVERN, Pa., March 24, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement ma...
MALVERN, Pa., Feb. 04, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...
MALVERN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tis...
Bruce Freedman, M.D. joins innovative MedTech company to advocate for more natural surgical hernia mesh options
MALVERN, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforceme...
TELA Bio, Inc. (TELA) CEO Tony Koblish on Q3 2020 Results - Earnings Call Transcript
Shares of TELA Bio (NASDAQ:TELA) were flat after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 97.65% over the past year to ($0.53), which missed t...
MALVERN, Pa., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforceme...
MALVERN, Pa., Nov. 9, 2020 /PRNewswire/ -- TELA Bio, Inc. ("TELA"), an innovative medtech company focused on solving the unmet needs in soft-tissue reconstruction, announced today that it will be featur...
MALVERN, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of...
MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforc...
MALVERN, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforc...
TELA Bio, Inc. (TELA) CEO Tony Koblish on Q2 2020 Results - Earnings Call Transcript
MALVERN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...
MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of t...
MALVERN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category ...
MALVERN, Pa., July 09, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforce...
MALVERN, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforce...
MALVERN, Pa., June 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforce...
MALVERN, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforce...
MALVERN, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...
MALVERN, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...
TELA Bio, Inc. (TELA) CEO Antony Koblish on Q1 2020 Results - Earnings Call Transcript
MALVERN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of ti...
MALVERN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category...
TELA Bio, Inc. (TELA) CEO Antony Koblish on Q4 2019 Results - Earnings Call Transcript
MALVERN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...
MALVERN, Pa., Jan. 29, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...
MALVERN, Pa., Jan. 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...
MALVERN, Pa., Dec. 06, 2019 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...
About TELA
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine... [Read more...]
| Industry Medical Devices | IPO Date Nov 8, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol TELA |
Financial Performance
In 2020, TELA Bio's revenue was $18.21 million, an increase of 17.91% compared to the previous year's $15.45 million. Losses were -$28.79 million, 28.4% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for TELA Bio stock is "Buy." The 12-month stock price forecast is 20.00, which is an increase of 31.06% from the latest price.